Does value vary by stakeholder perspective?
According to Innovation and Value Initiative Executive Director Darius Lakdawalla, the answer is yes. Here is his interview response on AJMCtv.
Tag: IVI
Do the US and UK health care systems have anything in common?
The United Kingdom’s National Health Services provides universal health coverage at not cost to patients. On the other hand, in the U.S. not all people have insurance, and further insurance can be provided by public entities (e.g., Medicare, Medicaid), private and employer-provided health insurance, and other sources. Whereas the NHS system is highly centralized, the U.S.…
The Case For Patient-Centered Assessment Of Value
Value assessments are all the rage these days. From ASCO to ESMO, from MSKCC to AHA/ACC, from AMCP to ICER, there are a variety of value frameworks (and acronyms) out there. In the Health Affairs blog today, Alan Balch and Darius Lakdawalla make the case that treatment value should be measured from a patient-centered approach.…
Applying Cost Effectiveness Analysis to all Health Care Interventions
That is the topic of a Health Affairs blog post published today by James Baumgarder and Peter Neumann. An excerpt is below. Cost-effectiveness analysis (CEA) is an important tool for assessing and pointing the way toward better health care efficiency. The number of published CEAs on health care interventions has blossomed, averaging 34 per year…
The Price of Everything and the Value of Nothing
That is the title of an article in Eye for Pharma which interviews me about measuring value in health care. The article highlights a number of issues related to value measurement, health policy and the healthcare marketplace. The article also describes the launch of the Innovation and Value Initiative, a broad coalition of providers, payers, patient advocates,…
Figuring out how to measure value
Unlike some other organizations, [the Innovation and Value Initiative (IVI)] is not interested in a top-down, bureaucratic process for setting prices or measuring value, says Shafrin. Rather, IVI aims to disseminate best practices for measuring value and reimbursing treatments based on this value. “We are looking at balancing innovation and value,” he says. “Some people are…
Assessing Healthcare Value: The Need for a Decentralized And Scientific Approach
Tomas Philipson has an interesting post in Forbes describe how value should be incorporated into the U.S. healthcare system but should be done in way suited for the American market. The American healthcare system is at a crossroads. Shifting to a system that reimburses based on value, rather than volume, of care requires changes in how we…
The AMA on value-based drug pricing
The American Medical Association released a statement yesterday in support of value-based pricing of pharmaceuticals. However, AMA claims that value-based pricing should follow the following core principles. Value-based prices of pharmaceuticals should be determined by objective, independent entities. They also should be evidence-based and the result of valid and reliable inputs and data that incorporate…
The Innovation and Value Initiative (IVI) has launched
I’m excited to announce that the Innovation and Value Initiative (IVI) has just launched. I will be serving as the Director of Research. Below, I have reposted the IVI press release so you can lear more about the initiative. Precision Health Economics today launched the Innovation and Value Initiative (IVI), a multi-stakeholder scientific initiative to…
How do we measure the value of and pay for biomedical innovation?
Dana Goldman, Samuel Nussbaum, and Mark Linthicum have an interesting post on the Health Affairs blog about innovation, value measurement and pricing. The article mentions the new Innovation and Value Initiative, where I serve as the Director of Research. An excerpt is below. New pricing mechanisms are needed to effectively link prices to value; we…